PixarBio Corp. To Establish Medical Research Center-Corporate Headquarters In Medford, Massachusetts
12/13/2013
Located in close proximity to its innovation roots at Harvard and MIT, PixarBio Corp. said it will have capacity to quickly expand beyond biomaterials needed for Parkinson’s disease to include biomaterials for Epilepsy.
“We are building a home for our world renowned and award winning team of researchers to drive innovation and accelerate the development of new treatment options for Parkinson’s disease. We’re confident that our optimized R&D model will generate key intellectual property permitting PixarBio to lead the development of next generation biomaterials for the treatment of Parkinson’s disease as well as a range of chronic neurological conditions,” says CTO Randy Holmes-Farley, PhD.
Frank Reynolds, PixarBio’s CEO adds, “We’ll move to Medford, MA in early 2014 and get to work on achieving our objective of rapidly bringing a new Parkinson’s treatment to market. Along the way we’ll explore M&A in the biomaterials space while focusing on expanding our platform.”
Project Announcements
Australia-Based Woodside Energy Group Plans Calcasieu Parish, Louisiana, LNG Operations
05/03/2025
Techo-Bloc Plans Cayce, South Carolina, Manufacturing Operations
05/03/2025
Italy-Based A.D.R Axles USA Plans Perry, Iowa, Operations
04/30/2025
Dollar Tree Plans Marietta, Oklahoma, Distribution Operations
04/30/2025
Hitachi Energy Expands Bland, Virginia, Production Operations
04/28/2025
Amgen Expands New Albany, Ohio, Manufacturing Operations
04/28/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
The Location Economics of Advanced Nuclear
Q1 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
NEW NIMBYism: A Threat to The U.S. Economy
Q4 2024
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Forging Solid Foundations
Q1 2025